Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report) shares reached a new 52-week high on Tuesday . The stock traded as high as $43.21 and last traded at $42.11, with a volume of 278690 shares changing hands. The stock had previously closed at $41.87.
Gemini Therapeutics Stock Up 0.6 %
The company has a market cap of $1.82 billion, a P/E ratio of -41.87 and a beta of -0.12. The company’s 50-day moving average is $42.74 and its two-hundred day moving average is $47.40.
About Gemini Therapeutics
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Recommended Stories
- Five stocks we like better than Gemini Therapeutics
- Using the MarketBeat Dividend Tax Calculator
- Uber’s Earnings Beat: Rideshare and Delivery Surge
- Investing in Commodities: What Are They? How to Invest in Them
- Hims & Hers Reports Stellar Quarter: Stock Set for a Rally
- How to Read Stock Charts for Beginners
- Cloudflare Stock Flares Up on Solid EPS Beat and Raised Guidance
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
